A team led by scientists at Harvard Medical School, Massachusetts General Hospital, and the Broad Institute of MIT and ...

CAR T cells are patient-derived, genetically engineered immune cells. They are "living drugs" and constitute a milestone in modern medicine. Equipping T cells, a key cell type of the immune system, ...

The range of autoimmune diseases treatable with chimeric antigen receptor (CAR) T-cell therapy could be much broader than ...

Researchers from Mass General Brigham and the Broad Institute of MIT and Harvard have identified genetic modifications that ...

Researchers found that zeaxanthin, long associated with eye health, may also boost the body’s immune response against cancer.

Cutaneous squamous-cell carcinoma (SCC) is primarily caused by oncogenesis mediated by ultraviolet radiation, and β-human papillomavirus (β-HPV) is believed to be a mere facilitator that is ...

Philadelphia’s pioneering cancer scientist, Carl June, has been honored with two awards in the last month for his seminal work engineering the body’s immune system to fight cancer. June has spent ...

Physical function correlated with outcomes among patients who underwent CAR T-cell therapy. Those with worse physical function had higher risk for death and ICANS. Poor physical function correlated ...

In a new study published in GEN’s sister peer-review journal, GEN Biotechnology, titled, “Exploring Structure-Function Relationships in Engineered Receptor Performance Using Computational Structure ...

Patients with recurring prostate cancer who were treated with a new PSMA-targeted radioligand therapy before stereotactic ...